59 results about "Lectin binding" patented technology

The present invention provides a pharmaceutical composition for treating chronic hepatitis C characterized by comprising at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators (for example, CpG oligo deoxynucleotide, GM-CSF, IL-4, LPS, CD40L, polyI:C, TNF-a and IFN-?) and lectin-binding substances (for example, mannose carbohydrate, fucose carbohydrate and anti-lectin antibody); and a method of treating chronic hepatitis C by using such active ingredient(s). In the above pharmaceutical composition and therapeutic method, it is possible to use INF-a together with these active ingredients.

Methods and kits for assessing the presence of, and for detecting cancer, notably oral cancer, are disclosed. Such methods and kits use one or more lectins operably linked to a fluorophore, wherein the lectin binds differentially to cancerous and non-cancerous tissues, and wherein the fluorophore facilitates visualizing the differential binding. The lectins are applied to the oral mucosa of a subject, the fluorophore is exposed to light, and cancerous regions of the mucosa are visualized. In certain embodiments, the lectin specifically binds to one or more of a β-galactoside, an α- or β-N-acetylglucosamine, or a sialic acid moiety.

The invention discloses enzyme-lectin conjugate nano-particles and a preparing method thereof. According to the preparing method, raw materials for preparing the enzyme-lectin conjugate nano-particles include enzyme, lectin and a cross-linking agent, as well as magnetic nano-particles and/or a reductant. The enzyme-lectin conjugate nano-particles can be prepared from, by weight, 10 parts of enzyme, 50-500 parts of lectin, 0.1-300 parts of cross-linking agent and 0-1 parts of reductant. The enzyme-lectin conjugate nano-particles can also be prepared from, by weight, 10 parts of enzyme, 50-500 parts of lectin, 1-100 parts of magnetic nano-particles, 0.1-300 parts of cross-linking agent and 0-1 parts of reductant. The enzyme-lectin conjugate nano-particles are dispersed in aqueous solution at a conventional catalytic reaction temperature and have high catalytic activity. Lectin combined with enzyme can attract saccharides substrates, so that the aqueous-phase activity of the conjugate can be further improved. Enzyme molecules in enzyme-lectin-magnetic nano-particle conjugate nano-particles are adsorbed by lectin, covalent cross-linking occurs between enzyme molecules and lectin and magnetic nano-particles, and therefore recoverability of the catalyst is realized based on the realization of high catalytic activity.

The invention discloses a method for detecting glycoprotein. The method comprises the following steps of: marking the glycoprotein by using zinc oxide quantum dots; meanwhile, immobilizing an agglutinin layer on a chip in an electrolytic cell; specifically binding the glycoprotein marked by the zinc oxide quantum dots with agglutinin on the chip in a series of glycoprotein solutions to be determined of known concentrations; connecting the zinc oxide quantum dots marked on the glycoprotein to the chip; and determining the agglutinin by using dissolving voltammetry of marking the glycoprotein with the zinc oxide quantum dots. Since the marked glycoprotein has different binding capacities to the glycoprotein to be determined and the agglutinin, the glycoprotein marked on the chip is substituted by the glycoprotein to be determined of different concentrations, and the concentration of zinc ions which are remained on the chip and dissolved out is determined by using the dissolving voltammetry to establish relation between the concentration of the zinc ions and the concentration of the glycoprotein so as to determine the concentration of the glycoprotein to be determined.

The present invention provides a method and a kit for accurately predicting the prognosis (mortality rate) and risk of developing hepatocellular carcinoma in liver cirrhosis patients. The present invention provides: a method by which an 'index for evaluating the risk of developing hepatocellular carcinoma, 'which is used for predicting the prognosis and risk of developing hepatocellular carcinomain liver cirrhosis patients, is calculated as the ratio of CSF1R that contains WFA/VVA-binding sugars relative to the total CSF1R content of bodily fluid (blood serum) (WFA+-CSF1R%); and a method by which a 'prognosis evaluation index ' is calculated as the amount of CSF1R that contains WFA/VVA-binding sugars (WFA+-CSF1R ng/mL). Furthermore, an optimal cutoff value was determined for each of the indices, and it was proven that: the risk of developing hepatocellular carcinoma was significantly high when the 'index for evaluating the risk of developing hepatocellular carcinoma ' in a subject wasequal to or greater than the optimal cutoff value; and the prognosis was significantly poor when the 'prognosis evaluation index ' was equal to or greater than the optimal cutoff value. In addition,anti-CSF1R antibodies (CSR-1-30), which are exceptional for detecting CSF1Rs such as CSF1Rs that contain WFA/VVA-binding sugars in a bodily fluid sample, were provided. It was discovered that srWFA and VVA lectins other than WFA lectins can be used, and it was additionally proven that measuring the amount of CSF1R that binds to a CSF1R-specific lectin is preferable to measuring the total amount ofCSF1R. It was also possible to provide, inter alia, a kit for measuring the 'prognosis evaluation index ' and/or 'index for evaluating the risk of developing hepatocellular carcinoma ' in a liver cirrhosis patient, the kit including these anti-CSF1R antibodies and lectins as constituent elements.

Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.